Jyong Biotech (MENS) Accounts Payables (2024 - 2025)
Jyong Biotech's (MENS) quarterly Accounts Payables came in at $2000.0 in Q4 2025, down 33.33% year-on-year from $3000.0 in Q4 2024, and down 33.33% quarter-over-quarter from $3000.0 in Q2 2025.
Jyong Biotech (MENS) Accounts Payables (2024 - 2025) Analysis & Trends
Jyong Biotech's Accounts Payables history runs 2 years deep, the most recent figure standing at $2000.0 for Q4 2025.
- On a quarterly basis, Accounts Payables fell 33.33% year-over-year to $2000.0 in Q4 2025; TTM through Dec 2025 was $2000.0, a 33.33% decrease from a year earlier, with the FY2025 full-year figure at $2000.0, down 33.33% from the prior year.
- Accounts Payables eased to $2000.0 in Q4 2025 per MENS's latest filing, from $3000.0 in the prior quarter.
- Across five years, Accounts Payables topped out at $3000.0 in Q4 2024 and bottomed at $2000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 5.74 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 10.62 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 423.55 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 694,346.76 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 489.30 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.03 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.52 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 80.54 Mn |
| 10 | Jyong Biotech | 197.86 Mn | 197.86 Mn | - | 2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2,000.00 |
| Jun 30, 2025 | 3,000.00 |
| Dec 31, 2024 | 3,000.00 |